Search This Blog

Monday, January 29, 2024

Karuna's KarXT tops Evaluate's most anticipated drug list

 

Pharma analytics group Evaluate Vantage has ranked Karuna Therapeutics' (KRTX) lead asset, KarXT as the most anticipated drug.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)